Research
Molecular
Orlistat's peak concentration stayed below 5 ng/mL, indicating minimal systemic absorption.
The low systemic absorption suggests a reduced risk of systemic side effects from orlistat.
StrongSupportsmedium confidence
Orlistat's peak concentration stayed below 5 ng/mL, and acarbose plasma levels were mostly undetectable, indicating minimal systemic absorption.
Why this rating
The study design involved blood sample collection for pharmacokinetic analysis.
Source
A Comparative Analysis of the Pharmacodynamic and Pharmacokinetic Properties of 2 Controlled‐Release Formulations Versus a Marketed Orlistat Product
Stefan Grudén et al. · Clinical Pharmacology in Drug Development · 2025
other · n=20
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →